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individual level by logistic regression. Results: At the time of the survey, 19.5% 
of the Portuguese population with ages between 50 and 64 years old were officially 
retired. A larger average number of major chronic diseases per capita was found 
among those with early retirement when compared to active workers in the same 
range of age (2.0 vs. 1.4 p< 0.001). RD were particularly prevalent among early retirees 
when compared with employees (43.3% vs. 32.1%, p< 0.001). The following OR and 
PAF (adjusted by age, sex and region and unadjusted) were obtained: RD (OR:1.3-
1.4; PAF:7.3-9.7), chronic pain (OR:1.4-1.4; PAF:6.6-7.2), hypertension [OR:1 (NS) 
-1.3; PAF:1.1-7.1], diabetes [OR:1 (NS) -1.2 (NS); PAF:0-2.4], renal impairment (OR:3.3 
-3.4; PAF:2.7-3.2), respiratory diseases (OR:1.5-1.7; PAF:1.5-2.1), stroke (OR:3.2-3.6; 
PAF:2.6-3.2), myocardial infarction [OR:1.2 (NS) -1.9; PAF:0.3-1.1], cancer (OR:2.1-
1.9; PAF:2.1-2.1), depression (OR:1.5-1.2 (NS); PAF:4.8-2.8) and anxiety (OR:1.6-1.5; 
PAF:3.7-3.5) with NS standing for not statically significant. ConClusions: From a 
public health angle, PAF is a good measure of the importance of a risk factor, taking 
into account both the strength of the association with the outcome and its preva-
lence in the population. Among all major chronic diseases, RD had the highest PAF 
estimates for early retirement in Portugal.
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objeCtives: To assess cost of pharmacotherapy in Polish patients with rheu-
matoid arthritis (RA) in relation to disease activity (DAS28-CRP) and disability 
(HAQ-DI). Methods: Data on drug consumption was collected during a prospec-
tive one center cohort observational study of non-selected RA patients discharged 
from tertiary academic hospital. At enrollment patients were divided according 
to DAS28-CRP and HAQ-DI. Observational period was 6 months. Spearman rang 
correlation coefficient and test of its significance were used to investigate the rela-
tionship of cost of pharmacotherapy with disease activity and disability. Mean total 
cost of drugs and mean cost of drugs covered by public payer were calculated in 
PLN at 2014 prices (1 EURO= 4.2 PLN in 2014). Results: DAS28-CRP was ≤ 5.1 in 124 
patients (group A) and > 5.1 in 83 patients (group B). HAQ-DI was > 2 in 51 patients 
(group I), > 1 and ≤ 2 in 88 patients (group II), ≤ 1 in 66 patients (group III). Mean cost 
of pharmacotherapy per patient was 1010 PLN in group A and 858 PLN in group B, 
1078 PLN in group 1, 981 PLN in group II and 745 in group III. The differences between 
groups were not statistically significant. Public payer covers only 36-40% of the drugs 
cost. ConClusions: These results represent the current use of drugs in the popu-
lation of Polish RA patients under real-life conditions and indicate that there is no 
impact of disease activity and disability on the cost of pharmacotherapy due to RA.
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objeCtives: In the light of future arrival of subcutaneous (SC) formulation of 
tocilizumab for the treatment of moderate to severe active rheumatoid arthritis, 
a multidimensional analysis has been performed in order to evaluate potential 
impact of introducing SC formulation vs. intra-venous (IV) one from the perspective 
of both patients and hospitals in Italy. Methods: The analysis was conducted in 
three Italian Rheumatology centers (AO-S. Anna-Ferrara, AO-Verona, UOS-Valeggio-
sul-Mincio) through a questionnaire administered to clinicians and nurses. A 60 
minutes day-hospital administration for IV and 20 seconds-1 minute administration 
for SC selfinjector or pre-filled syringe administered at home (excluding the first 
administration) were assumed. Monitoring visits were considered as 1 per month 
for IV and 1 every three months for SC. Four impact areas were evaluated: patient’s 
drug-administration time and costs (including transportation time and cost and loss 
of productivity), drug-administration related hospital-personnel time, drug wastage 
and patient risk profile evaluated through Failure Models and Effect Analysis. A one 
year time horizon was considered. Results: The analysis showed that the new SC 
formulation, compared to IV, could have a significant impact in terms of: patient 
time saving (- 91% of the time for the administration of therapy), patient costs 
(-86%), clinicians and nurses time saving measured as Full Time Equivalent (- 59% 
for clinicians and -94 % for nurses), drug wastage (-100%), and patient risk profile 
(-93%). ConClusions: The subcutaneous formulation of tocilizumab could have 
several organizational and management impacts. From the hospital perspective it 
could lead to reduction of medical resources consumption with the possibility to 
re-allocate them in other medical activities. From the patient perspective the new 
SC formulation could lead to time savings and costs reduction with a potential 
improvement of patient quality of life.
MuSCular-Skeletal diSorderS – Patient-reported outcomes & Patient 
Preference Studies
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objeCtives: Conduct a systematic review and meta-analysis of published litera-
ture on persistence with denosumab in patients with osteoporosis. Methods: 
Ps patients had dominantly (54%) low disease activity, in RA group mostly (51%) the 
moderate activity was observed, while the most frequent disease activity category 
for CD patients was remission (39%). Mean annual cost of overall work impairment 
(presenteeism and absenteeism cost together) amounted to PLN 29 727 for RA, PLN 
24 434 for Ps and PLN 23 682 for CD. Cost of loss of productivity due to RA ranged 
from PLN 15 069 for patients in remission to PLN 41 296 for highly active disease. For 
Ps it was respectively PLN 13 846 and PLN 44 009 and for CD PLN 15 543 and PLN 63 
771. ConClusions: Productivity loss among workers with CD, Ps and RA generates 
significant costs for society which rises with disease activity.
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objeCtives: To estimate the long-term productivity costs (PC) and their determinants 
associated with absenteeism and permanent work disability (WD) in Finnish patients 
with early rheumatoid arthritis (RA) available to workforce at baseline. Methods: 
A cohort of subjects with early RA was created by identifying the new cases of RA 
from the national register of the Social Insurance Institution (SII) in Finland, who 
were granted a special reimbursement of anti-rheumatic medications for rheumatoid 
factor positive (ICD-10 code: M05) or negative RA (M06) in 2000 – 2007. The obtained 
dataset was enriched by cross-linking with the national databases about the sub-
jects’ annual incomes, WD days, and permanent disability pensions. The human 
capital approach was applied to estimate PC based on subjects’ the annual number of 
absenteeism days and incomes. The PC were estimated and expressed as per patient-
observation year. Hurdle regression analysis was applied to study the determinants 
of PC. Sensitivity analyses were conducted to test the robustness of the obtained 
results. Results: The study cohort comprised 7,831 subjects with early RA in paid 
jobs. The mean age (SD) of subjects was 46 years (11) and 71 % were women. Mean 
(bootstrapped 95%CI) annual PC per patient-observation year was 4,574€ (95% CI 
4,469€ to 4,680€ ). The PC increased progressively over the years. The use of metho-
trexate-based combination therapies during the first three months after RA diagnosis 
reduced significantly the cumulative PC during the follow-up. ConClusions: So 
far the majority of the productivity cost studies have been based on cross-sectional 
data. However, the results of the present study provide unique evidence about the 
longitudinal economic burden of RA over the course of disease. The results highlight 
the need for treatment strategies with predefined targets and tight control of disease 
activity in the early course of disease to reduce the long-term burden of RA.
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objeCtives: To study the trends in work productivity loss pre- and post-diagnosis 
of incident rheumatoid arthritis (RA) and compare it to patients with osteoarthritis 
(OA) undergoing knee or hip replacement surgery. Methods: Retrospective register 
study conducted using Swedish national registers. Patients of working age with an 
incident diagnosis of RA between 2003 and 2009 were identified in the National 
Patient Register (n= 14900). OA patients undergoing surgery were identified during 
the same period and considered as a reference group (n= 34240). Monthly productiv-
ity loss twelve months pre-diagnosis to twelve months post-diagnosis was evaluated 
in the base case. Productivity loss was defined as the sum of net sick leave days and 
net disability pension days as recorded in the Social Insurance Register. Results: 
Monthly productivity loss gradually increased during the months leading up to RA 
diagnosis, peaking the month after diagnosis (mean 14.7 days/month). The same 
pattern was observed in the OA group in relation to time of surgery, although the 
increase in productivity loss the months post-surgery was considerably larger than 
the corresponding increase in the RA patients, peaking the second month following 
surgery (28.5 days/month). Twelve months post-surgery, the OA patients returned 
to levels of productivity loss similar to those seen six months pre-surgery (12.3 
days/month vs. 12.7 days/month, respectively). This reversal was not mirrored by 
the RA patients, who stabilized at an elevated level of productivity loss post- com-
pared to pre-diagnosis levels (12.1 days/month vs. 9.6 days/month). ConClusions: 
This study illustrates the unmet needs in RA. The partial reversal in work ability 
post-diagnosis, in contrast to the almost complete reversal seen in OA patients 
post-surgery, highlights the need for improved treatment options in RA; while the 
gradual loss of work ability leading up to diagnosis highlights the need for interven-
tion earlier in the disease process.
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objeCtives: Chronic diseases and in particular rheumatic diseases (RD) may lead 
to early retirement, generating substantial indirect costs to society. We compare 
RD to other major chronic diseases regarding their impact on the likelihood of 
early retirement in the Portuguese population. Methods: The study population 
consisted of all people between 50 and 64 years of age (3,762 men and 4,241 women) 
who participated in the Portuguese National Health Survey, conducted in 2005/2006. 
Self-reported data were collected on health, sociodemographic and occupational 
factors. The effects of RD and other chronic diseases on the likelihood of early retire-
ment and the population attributable fractions (PAF) estimates were obtained at the 
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objeCtives: Osteoporosis treatment involves several therapeutic tools, includ-
ing long-term drug therapy. Subjects with chronic disorders are more likely to be 
non-adherent and/or non-persistent to treatment than those with other diseases. 
Adherence is the extent to which patients take medication as prescribed by their 
physicians, whereas persistence is the time from treatment initiation to discontinu-
ation. Lack of persistence is common among subjects using oral anti-osteoporotic 
drugs, and leads to increased risk of fragility fracture. The aim of our study is to 
analyze the rates and reasons for discontinuation of anti-osteoporotic drugs in the 
Campania Region. Methods: The study was a retrospective cohort study. Patients, 
aged ≥ 40 years, were enrolled if at least one prescription for any antiosteoporotic 
drugs had been filled from July 1, 2009 through June 30, 2010. Data were retrieved 
from an administrative database of medications prescription in Campania region. 
Patients were followed from the index date until the antiosteoporotic therapy dis-
continuation or end of the observation period (June, 30, 2011). Results: A total of 
30,048 were incident users of anti-osteoporotic drugs: 1, 731 (5.8%) males and 28,317 
(94.2%) females. The mean age [SD] of the cohort was 69.0 [10.0] years. Weekly bis-
phosphonate (51.1%), was the most commonly prescribed drug. In the overall cohort 
study, persistence rates were 34, 8% after 6 months, 13, 4% at one year. A multivariate 
Cox proportional hazard analysis showed that daily regimen (HR 1,9) treatments 
remained at a higher risk of early discontinuation compared to weekly regimen 
therapies. Patients who started treatment with a co-prescription with calcium and 
vitamin D had a lower risk of early discontinuation (HR 0.7). ConClusions: Our 
data showed that the persistence to osteoporosis therapy is significantly worse 
than reported in literature. A better osteoporosis management should include drugs 
with less frequent dosing, to obtain both an increase in rate of persistence and a 
reduction in side-effect.
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objeCtives: In this study we determined the characteristics of patients with RA who 
used these aids, and the association of reminder use with adherence. Methods: 
201 patients with RA were included in this prospective cohort study examining 
treatment adherence. At baseline patients were asked if they used any special 
reminders such as pill containers, calendars, or diaries. Patients completed two self-
reported adherence questionnaires: the Compliance Questionnaire Rheumatology 
and the Adult AIDS Clinical Trials Group adherence questionnaire. Disease activity 
measures included number of swollen joints, number of tender joints, disease activ-
ity score (DAS28), and patient global assessment. Functional status was evaluated 
with the modified Health Assessment Questionnaire (MHAQ). Results: Mean age 
of the patients was 51 years, 75% were female, 53% were Hispanic, 25% white, and 
21% African American. Sixty-eight (34%) patients reported using a reminder: 53 
(26%) used special pill containers, 12 (6%) used calendars, and 3 (1%) diaries. Factors 
associated with the use of reminders were older age (p= 0.004), being white vs. 
Hispanic or African American (p= 0.003), being male vs. female (p= 0.005). Working 
patients were less likely to report using reminders (p= 0.006). No association was 
observed between education levels and use of aids. Use of reminders was associ-
ated with domains of self-reported adherence: adherence while away from home 
(r= 0.16, p= 0.03), when busy (r= 0.16, p= 0.03), and when running out of pills (r= 0.15, 
p= 0.04). ConClusions: Older patients, males, and whites were more likely to use 
these aids, more often pill containers. Our study shows that reminders can assist 
patients with RA in taking their medications, particularly in situations when they 
are most prone to forget including being away from home or busy. Use of reminders 
should be encouraged by providers as a low cost aid to enhance adherence.
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objeCtives: The objective of this study was to describe persistence with subcu-
taneous biologic over 12 months for newly treated PsA patients and evaluate the 
impact of prior DMARD use. Methods: This was a retrospective analysis using IMS 
Disease Analyzer-Germany, an electronic medical records database. Adult (≥ 18 years 
of age) PsA patients who initiated therapy with subcutaneous biologics between 
January 1, 2009 and June 30, 2012 were included in the analysis. The first subcutane-
ous biologic prescription date served as their index date. Continuous observation 
of at least 12 months pre- and post-index date was required. Patients who were 
prescribed any biologic during the pre-index period or diagnosed with rheumatoid 
arthritis, ankylosing spondylitis, crohn’s disease, or ulcerative colitis during the 
study period were excluded from the study population. A chi-square test was used 
to measure differences between patients with and without use of pre-index DMARD. 
A multivariate logistic regression was created to assess the impact of DMARD use 
on persistence, controlling for baseline characteristics. Results: A total of 197 
biologic-naïve PsA patients were selected. Of these, 89 were free of PsO. The mean 
(SD) age of the patients was 49 (11) years, with 50% being female. The majority of 
patients (61%) indexed on adalimumab, while the remainder indexed on etanercept 
(35%) and golimumab (4%). In the overall PsA population, the persistence rate with 
the index subcutaneous biologic was 54.3%, with similar results among those with 
and without DMARD use (53% vs 56%, respectively). Multivariate analysis did not 
identify any significant predictors for persistence, including DMARD use (OR: 1.05; 
A systematic review identified retrospective and prospective observational stud-
ies reporting 12-, 18-, or 24-month persistence with denosumab, an osteoporosis 
therapy approved in 2010. Searches covered the period January 2011─May 2014 and 
were conducted in the PubMed and EMBASE databases, and conference abstract 
supplements from ACR, AMCP, ASBMR, WCO-IOF-ESCEO, and ISPOR. To be eligible, 
studies needed to report at least one estimate of persistence with denosumab in 
patients with osteoporosis, have a clear definition of persistence, and be in English 
language. Using a random effects model, pooled estimates of denosumab per-
sistence were calculated for retrospective and prospective studies separately. A 
subgroup analysis was conducted based on geographical regions. Results: The 
search identified 338 unique citations in PubMed and EMBASE, and 200 confer-
ence abstracts. After applying the eligibility criteria, 11 studies were included in the 
final review and meta-analysis (7 retrospective; 4 prospective). All studies reported 
at least one estimate of 12-month persistence; 9 studies included females only. 
For retrospective studies, the pooled persistence estimates were 74.6% (95% CI: 
65.4-82.9) at 12 months, 67.6% (65.2-70.0) at 18 months, and 57.2% (51.8-62.5) at 24 
months. For prospective studies, the pooled estimate of 12-month persistence was 
89.0% (95% CI: 84.6-92.7). In the subgroup analysis, European studies had higher 
pooled 12-month persistence estimates compared with North American studies 
(retrospective: 78.6% vs. 68.9%; prospective: 91.5% vs. 85.3%). ConClusions: To 
our knowledge, this is the first systematic review and meta-analysis of persistence 
with denosumab in patients with osteoporosis. We identified a growing body of 
evidence, both prospective and retrospective, suggesting persistence to denosumab 
is higher than previously reported for other OP therapies1.1. Kothawala P, et al. Mayo 
Clinic. 2007; 82 (12): 1493-501.
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objeCtives: This study examined persistence over 12 months for RA patients who 
were newly treated with subcutaneous biologics, and assessed if there are differ-
ences between patients with and without prior DMARDs experience. Methods: 
In this retrospective cohort study using Electronic Medical Record database of IMS 
Disease Analyzer-Germany, adult (≥ 18 years old) RA patients with exposure to a 
subcutaneous biologic between January 1, 2009 and June 30, 2012 were identified. 
The first prescription date for the subcutaneous biologic agent was defined as 
their index date. Patients were excluded from the study if they were prescribed 
a biologic agent during the pre-index period, and/or diagnosed with ankylosing 
spondilitis, psoriatic arthritis, or other conditions treated with subcutaneous bio-
logics either pre- or post-index. A chi-square test was used to assess significant 
differences in the percentage of persistent patients between those with and with-
out DMARD use and a logistic regression model was used to control for differences 
in baseline demographic and clinical characteristics. Results: A total of 576 RA 
patients without prior biologic experience met the study selection criteria; 471 
were DMARD experienced and 105 were DMARD naive. The mean (SD) age of the 
patients was 57 (13), with 75% being female. The majority of patients indexed 
on etanercept (46%) or adalimumab (40%). Forty eight percent of the patients 
persisted on their index biologic over the 12 months post-index period, with the 
rate significantly higher among those with pre-index DMARD use (51% vs. 31%; 
p= 0.0012). After controlling for pre-index characteristics, patients with pre-index 
DMARD had 2.23 times the odds of being persistent compared to those without 
pre-index DMARDs (OR: 2.23, 95% CI: 1.37-3.62). ConClusions: Approximately 
half of biologic naïve RA patients were persistent over a 12-month period with 
their index subcutaneous biologic, with rates significantly higher among patients 
with pre-index DMARD.
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objeCtives: This study aimed to describe persistence with subcutaneous biologics 
among biologic naïve AS patients over 12 months, and to identify differences among 
patients with and without NSAID drug experience. Methods: This retrospective 
study used IMS Disease Analyzer-Germany, an electronic medical records database. 
Data for adult (≥ 18 years of age) AS patients with a prescription for subcutaneous 
biologic between January 1, 2009 and June 30, 2012 were used for this analysis. The 
index date was the date of the first subcutaneous biologic prescription. Prescription 
for any biologic during the pre-index period or diagnosis for rheumatoid arthritis, 
psoriatic arthritis or other conditions treated with subcutaneous biologics either 
in pre- or post-index qualified patients for exclusion from the study. Differences 
between pre-index NSAID naïve and experienced patients were measured using a 
chi-square test. A logistic regression model was used to further assess the impact 
of NSAID use on persistence, controlling for baseline characteristics. Results: The 
study cohort included a total of 108 biologic naïve AS patients, 72 with use of NSAIDs 
in the pre-index period. The mean age of the AS cohort was 42 years, with 70% of 
patients being male. Adalimumab, etanercept, and golimumab were initiated by 
61%, 28%, and 11% of patients, respectively. Persistence for at least 12 months with 
the index subcutaneous biologic was observed in 46.3% of the overall cohort, with 
similar results among those with and without NSAID use (47% vs 44%, respectively). 
Multivariate analysis confirmed similar persistence between those with and without 
pre-index NSAID (OR: 0.97; 95% CI: 0.39-2.44). ConClusions: Findings from this 
German study showed that less than half of AS patients are persistent with the 
index subcutaneous biologic over a 12 month period. Results were similar irrespec-
tive of prior use of NSAIDs.
